IL6 and COVID-19: In Cai et al., among patients with COVID-19, those with cancer had higher concentrations of inflammatory markers and cytokines (high-sensitivity C-reactive protein, procalcitonin, interleukin (IL)-2 receptor, IL-6, and IL-8) and fewer immune cells than did those without cancer, indicating that patients with cancer are more susceptible to immune dysregulation [17].